BDMD vs HLIT vs VIAV vs NVCR

For growth investors, Baird Medical Investment Holdings Limited (BDMD) is the stronger pick with 17.

7% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Baird Medical Investment Holdings Limited (BDMD) offers the better valuation at 3. 8x trailing P/E, making it the more compelling value choice. Analysts rate Viavi Solutions Inc. (VIAV) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Baird Medical Investment Holdings Limited (BDMD) is the cheapest at 3.

8x versus Viavi Solutions Inc. at 340. 3x. On forward P/E, Harmonic Inc. is actually cheaper at 21. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Viavi Solutions Inc.

(VIAV) delivered a total return of +212. 0%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: VIAV returned +715. 5% versus BDMD's -80. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Baird Medical Investment Holdings Limited (BDMD) is the lower-risk stock at 1.

15β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 92% more volatile than BDMD relative to the S&P 500. On balance sheet safety, Harmonic Inc. (HLIT) carries a lower debt/equity ratio of 32% versus 89% for Viavi Solutions Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Baird Medical Investment Holdings Limited (BDMD) is pulling ahead at 17.

7% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Viavi Solutions Inc. grew EPS 225. 0% year-over-year, compared to -54. 2% for Harmonic Inc.. Over a 3-year CAGR, HLIT leads at 10. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Baird Medical Investment Holdings Limited (BDMD) is the more profitable company, earning 33.

6% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 33. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDMD leads at 41. 4% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — BDMD leads at 88. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Harmonic Inc.

(HLIT) trades at 21. 8x forward P/E versus 55. 2x for Viavi Solutions Inc. — 33. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Viavi Solutions Inc.

(VIAV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+715. 5% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VIAV: +715. 5%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BDMD (Healthcare) and HLIT (Technology) and VIAV (Technology) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BDMD is a small-cap high-growth stock; HLIT is a small-cap quality compounder stock; VIAV is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.